Healthcare resource utilization in patients receiving quizartinib or placebo in combination with chemotherapy for newly diagnosed, FLT3-ITD+ acute myeloid leukemia: An analysis from the QuANTUM-first trial
Abstract
Introduction: The global, randomized, placebo (Pbo)-controlled, phase 3 QuANTUM-First trial (NCT02668653) evaluated quizartinib (Quiz), a novel oral FLT3 inhibitor, in combination with induction and consolidation chemotherapy, and as maintenance monotherapy in patients (pts) with newly diagnosed FLT3-ITD+ acute myeloid leukemia (AML). Quiz showed improved median (95% CI) overall survival of 31.9 months (mo; 21.0–not estimable) vs 15.1 mo (13.2–26.2) for Pbo (HR 0.78 [0.62–0.98]; P=0.032), leading to its approval for newly diagnosed FLT3-ITD+ AML. Intensive chemotherapy for AML incurs substantial healthcare resource utilization (HRU) due to prolonged hospitalization, requiring close monitoring and regular transfusions to manage myelosuppression. FLT3 inhibitors, including Quiz, are associated with myelosuppression as a class effect, predominantly neutropenia, thrombocytopenia, and anemia. We assessed HRU, including hospitalizations and transfusions, to evaluate the impact of myelosuppression in QuANTUM-First.
Methods:HRU was analyzed by treatment (Tx) arm and study phase (data cutoff August 13, 2021): induction chemotherapy (≤2 cycles), consolidation chemotherapy (≤4 cycles), and monotherapy maintenance (≤36 28-day [d] cycles). Hematopoietic stem cell transplantation (HSCT; no study drug administered) was at the investigators' discretion. For each pt, total length of hospitalization, length in each phase, and proportion of days hospitalized in the maintenance phase were…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 268 participants or records.
Read the paper
Related studies
- Quantum dots: synthesis, bioapplications, and toxicity
- A Guide to In Silico Drug Design
- Quantum Computing for Healthcare: A Review
- Automated in Silico Design of Homogeneous Catalysts
- Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach
- In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.